Drugs / AV-1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04273217 | Feb 2020 → Jul 2021 | — | AbViro LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06799741 | Jan 2025 → Mar 2026 | — | AbViro LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AV-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06799741 ↗ |
| Modality | Monoclonal antibody | “AV-1 is a human monoclonal antibody (mAb)” NCT04273217 ↗ |
| Route | Intravenous | “administered as a single IV infusion” NCT04273217 ↗ |